Overview

A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.

Status:
Recruiting
Trial end date:
2027-01-04
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest Huntington's Disease.
Phase:
Phase 2
Details
Lead Sponsor:
Hoffmann-La Roche